United Therapeutics announces additional $500M share repurchase program United Therapeutics announced that its board authorized the repurchase of up to an additional $500M of the company's common stock. This program will become effective on August 1, and will remain open for up to one year. The company also announced that it had recently completed its previously-announced repurchase program by purchasing a total of approximately 4.6 million shares of its common stock.
News For UTHR From The Last 14 Days
Check below for free stories on UTHR the last two weeks.
United Therapeutics jumps after court rules generic will infringe United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.